Wilson Sonsini Advises SR One on ARS Pharmaceuticals’ $55 Million Series D

On August 31, 2021, ARS Pharmaceuticals, Inc., a pharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions potentially leading to anaphylaxis, announced it closed on a Series D financing of $55 million led by SR One with participation from RA Capital Management, and one other U.S.-based, healthcare-focused fund, as well as existing investor, Deerfield Management. ARS will use the funds to advance Neffy™ through approval, to support initial launch activities, and to evaluate Neffy in clinical studies for additional indications. Neffy could provide an easy-to-use, convenient, and more reliable treatment for severe allergic reactions to food, medications, and insect bites that could lead to life-threatening anaphylaxis. Wilson Sonsini Goodrich & Rosati represented SR One in the transaction.

"This additional funding will allow us to focus on pre-launch activities for Neffy and additional research and development for a second indication for nasal epinephrine that we believe can add significant value to the ARS portfolio. This investment advances further work to prepare for launch of a reliable, easy-to-use, needle-free option for the treatment of a severe allergic reaction," said Richard Lowenthal, founder, chief executive officer, and president of ARS Pharma.

A Wilson Sonsini team including Dan Koeppen, Meg Burton, and Bridget Balisy represented SR One in the transaction.

For more information, please see the press release.